Drug Profile


Alternative Names: KF-15372; KW-3902; KW-3902 Injectable Emulsion; KW-3902IV; MK-7418

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko; Merck & Co
  • Class Neuroprotectants; Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure; Cognition disorders; Hypertension

Most Recent Events

  • 02 Sep 2009 Final safety and efficacy data from the PROTECT-1 and PROTECT-2 trials in Acute heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-2009)
  • 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in Canada (IV)
  • 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top